163 related articles for article (PubMed ID: 12948302)
1. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis.
Gandrud LM; Cheung JC; Daniels MW; Bachrach LK
J Pediatr Endocrinol Metab; 2003; 16(6):887-92. PubMed ID: 12948302
[TBL] [Abstract][Full Text] [Related]
2. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions.
Steelman J; Zeitler P
J Pediatr; 2003 Apr; 142(4):417-23. PubMed ID: 12712060
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
[TBL] [Abstract][Full Text] [Related]
5. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Bayram F; Tanriverdi F; Kurtoğlu S; Atabek ME; Kula M; Kaynar L; Keleştimur F
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):275-9. PubMed ID: 16607930
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
7. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
8. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
Brown JJ; Zacharin MR
J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
[TBL] [Abstract][Full Text] [Related]
10. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Lee YS; Low SL; Lim LA; Loke KY
Eur J Pediatr; 2001 Nov; 160(11):641-4. PubMed ID: 11760017
[TBL] [Abstract][Full Text] [Related]
11. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Forin V; Arabi A; Guigonis V; Filipe G; Bensman A; Roux C
Joint Bone Spine; 2005 Jul; 72(4):313-8. PubMed ID: 16038843
[TBL] [Abstract][Full Text] [Related]
12. Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens.
Martinez-Soto T; Pacaud D; Stephure D; Trussell R; Huang C
J Pediatr Endocrinol Metab; 2011; 24(5-6):271-4. PubMed ID: 21823522
[TBL] [Abstract][Full Text] [Related]
13. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
14. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.
Ninkovic M; Love S; Tom BD; Bearcroft PW; Alexander GJ; Compston JE
J Hepatol; 2002 Jul; 37(1):93-100. PubMed ID: 12076867
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pamidronate in juvenile osteoporosis.
Shaw NJ; Boivin CM; Crabtree NJ
Arch Dis Child; 2000 Aug; 83(2):143-5. PubMed ID: 10906023
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
Aris RM; Lester GE; Renner JB; Winders A; Denene Blackwood A; Lark RK; Ontjes DA
Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):941-6. PubMed ID: 10988110
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
19. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
